SK Biopharmaceuticals Valuation
Is A326030 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A326030 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: A326030 (₩89400) is trading above our estimate of fair value (₩21737.23)
Significantly Below Fair Value: A326030 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A326030?
Other financial metrics that can be useful for relative valuation.
| What is A326030's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | ₩6.95t |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 19.5x |
| Enterprise Value/EBITDA | -312x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does A326030's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 5.3x | ||
A000100 Yuhan | 2.9x | 7.2% | ₩5.4t |
A128940 Hanmi Pharm | 2.8x | 6.0% | ₩4.1t |
A008930 Hanmi Science | 1.9x | n/a | ₩2.3t |
A000250 Sam Chun Dang Pharm | 13.8x | n/a | ₩2.7t |
A326030 SK Biopharmaceuticals | 19.7x | 22.8% | ₩7.0t |
Price-To-Sales vs Peers: A326030 is expensive based on its Price-To-Sales Ratio (19.7x) compared to the peer average (5.3x).
Price to Earnings Ratio vs Industry
How does A326030's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?
Price-To-Sales vs Industry: A326030 is expensive based on its Price-To-Sales Ratio (19.7x) compared to the KR Pharmaceuticals industry average (0.9x).
Price to Sales Ratio vs Fair Ratio
What is A326030's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 19.7x |
| Fair PS Ratio | 10.3x |
Price-To-Sales vs Fair Ratio: A326030 is expensive based on its Price-To-Sales Ratio (19.7x) compared to the estimated Fair Price-To-Sales Ratio (10.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | ₩89,500.00 | ₩106,133.33 +18.6% | 21.5% | ₩130,000.00 | ₩51,000.00 | n/a | 15 |
| May ’25 | ₩87,600.00 | ₩106,133.33 +21.2% | 21.5% | ₩130,000.00 | ₩51,000.00 | n/a | 15 |
| Apr ’25 | ₩92,000.00 | ₩103,400.00 +12.4% | 21.6% | ₩130,000.00 | ₩50,000.00 | n/a | 15 |
| Mar ’25 | ₩96,900.00 | ₩105,062.50 +8.4% | 21.4% | ₩130,000.00 | ₩50,000.00 | n/a | 16 |
| Feb ’25 | ₩90,000.00 | ₩105,062.50 +16.7% | 21.4% | ₩130,000.00 | ₩50,000.00 | n/a | 16 |
| Jan ’25 | ₩100,400.00 | ₩105,333.33 +4.9% | 21.6% | ₩130,000.00 | ₩54,000.00 | n/a | 15 |
| Dec ’24 | ₩85,300.00 | ₩105,333.33 +23.5% | 21.6% | ₩130,000.00 | ₩54,000.00 | n/a | 15 |
| Nov ’24 | ₩75,600.00 | ₩105,266.67 +39.2% | 21.9% | ₩130,000.00 | ₩54,000.00 | n/a | 15 |
| Oct ’24 | ₩86,200.00 | ₩106,785.71 +23.9% | 20.2% | ₩130,000.00 | ₩65,000.00 | n/a | 14 |
| Sep ’24 | ₩82,100.00 | ₩106,266.67 +29.4% | 19.7% | ₩130,000.00 | ₩65,000.00 | n/a | 15 |
| Aug ’24 | ₩90,000.00 | ₩96,714.29 +7.5% | 13.3% | ₩110,000.00 | ₩65,000.00 | n/a | 14 |
| Jul ’24 | ₩80,900.00 | ₩94,923.08 +17.3% | 13.5% | ₩110,000.00 | ₩65,000.00 | n/a | 13 |
| Jun ’24 | ₩74,700.00 | ₩95,285.71 +27.6% | 13.1% | ₩110,000.00 | ₩65,000.00 | n/a | 14 |
| May ’24 | ₩69,000.00 | ₩94,692.31 +37.2% | 16.5% | ₩110,000.00 | ₩51,000.00 | ₩87,600.00 | 13 |
| Apr ’24 | ₩63,300.00 | ₩94,692.31 +49.6% | 16.5% | ₩110,000.00 | ₩51,000.00 | ₩92,000.00 | 13 |
| Mar ’24 | ₩66,700.00 | ₩95,500.00 +43.2% | 18.3% | ₩120,000.00 | ₩51,000.00 | ₩96,900.00 | 12 |
| Feb ’24 | ₩71,600.00 | ₩95,916.67 +34.0% | 18.4% | ₩120,000.00 | ₩51,000.00 | ₩90,000.00 | 12 |
| Jan ’24 | ₩72,100.00 | ₩95,916.67 +33.0% | 18.4% | ₩120,000.00 | ₩51,000.00 | ₩100,400.00 | 12 |
| Dec ’23 | ₩72,700.00 | ₩95,916.67 +31.9% | 18.4% | ₩120,000.00 | ₩51,000.00 | ₩85,300.00 | 12 |
| Nov ’23 | ₩58,500.00 | ₩99,000.00 +69.2% | 21.9% | ₩122,000.00 | ₩51,000.00 | ₩75,600.00 | 9 |
| Oct ’23 | ₩56,900.00 | ₩102,222.22 +79.7% | 19.0% | ₩122,000.00 | ₩65,000.00 | ₩86,200.00 | 9 |
| Sep ’23 | ₩71,200.00 | ₩102,222.22 +43.6% | 19.0% | ₩122,000.00 | ₩65,000.00 | ₩82,100.00 | 9 |
| Aug ’23 | ₩78,500.00 | ₩102,857.14 +31.0% | 19.0% | ₩122,000.00 | ₩73,000.00 | ₩90,000.00 | 7 |
| Jul ’23 | ₩70,400.00 | ₩108,500.00 +54.1% | 15.0% | ₩122,000.00 | ₩75,000.00 | ₩80,900.00 | 6 |
| Jun ’23 | ₩86,700.00 | ₩118,875.00 +37.1% | 18.3% | ₩150,000.00 | ₩75,000.00 | ₩74,700.00 | 8 |
| May ’23 | ₩91,800.00 | ₩118,875.00 +29.5% | 18.3% | ₩150,000.00 | ₩75,000.00 | ₩69,000.00 | 8 |
Analyst Forecast: Target price is less than 20% higher than the current share price.